Discovered and developed by Abbott scientists, Atrasentan is a selective endothelin-A receptor (ETAR) antagonist which is presently being investigated as a potential treatment for diabetic kidney disease.
These conclusions were drawn from the findings of a Phase 2, eight-week, low dose-ranging study of atrasentan in patients with diabetic kidney disease in which patients were equally randomized to placebo, and three separate doses of Atrasentan.
The study’s primary endpoint was a mean change in urine albumin-to-creatinine ratio (UACR) from baseline to each treatment visit compared to standard of care.
University of Utah Health Sciences Center professor of medicine, lead investigator for the study Donald Kohan said that these early study results suggest that Atrasentan may have an additional therapeutic role for albuminuria reduction when added to the current standard of care for patients with type 2 diabetes.
Abbott Divisional vice president for dyslipidemia and renal James Stolzenbach said that Abbott looks forward to continued study of Atrasentan in longer, outcome-driven clinical trials.